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Abstract  51 
Context: The Short Synacthen Test (SST) is the gold standard for diagnosing adrenal 52 
insufficiency. It requires invasive administration of Synacthen, venous sampling and is 53 
resource-intensive.  54 
Objective: To develop a nasally administered SST, with salivary glucocorticoids 55 
measurement, to assess the adrenal response.  56 
Design: We conducted five studies: four open-label, sequence-randomised, crossover, 57 
pharmacodynamic studies testing six doses/formulations and a repeatability study. 58 
Additionally, pharmacokinetic analysis was undertaken using our chosen formulation, 500 59 
µg tetracosactide with mucoadhesive chitosan, Nasacthin003, in our paediatric study.  60 
Setting: Adult and children’s Clinical Research Facilities.  61 
Participants: 36 healthy adult males and 24 healthy children.  62 
Intervention: We administered all six nasal formulations using a CE marked atomisation 63 
device. The intravenous comparators were 250 µg or 1 µg SST.  64 
Main Outcome Measures: We analysed paired blood and saliva samples for plasma 65 
cortisol and salivary cortisol and cortisone.  66 
Results: The addition of chitosan to tetracosactide and dose escalation increased peak 67 
cortisol response (p=0·01 and 0·001 respectively). The bioavailability of Nasacthin003 68 
was 14·3%. There was no significant difference in plasma cortisol at 60 minutes between 69 
500 µg Nasacthin003 and 250 µg intravenous Synacthen (p=0.17). The repeatability 70 
coefficient at 60 minutes was 105 nmol/l for intravenous Synacthen and for salivary 71 
cortisol and cortisone was 10·3 and 21·1 nmol/L respectively. The glucocorticoid response 72 
in children was indistinguishable from that of adults. 73 
Conclusions: Nasal administration of Nasacthin003 generates equivalent plasma cortisol 74 
values to the 250 µg intravenous SST and, with measurement at 60 minutes of salivary 75 
cortisol or cortisone, provides a non-invasive test for adrenal insufficiency.  76 
5 
Introduction 77 
The Short Synacthen Test (SST), or ACTH (cosyntropin) stimulation test, is the most 78 
commonly used diagnostic test for adrenal insufficiency (AI) and the recommended, 79 
gold standard test for primary AI.1,2,3 The test involves either intravenous or 80 
intramuscular injection of synthetic ACTH(1-24) (tetracosactide) and blood sampling 81 
at 30-60 minutes to quantify the plasma cortisol response. Use of the test is 82 
increasing.3,4 For most healthcare providers the test is time-, labour- and resource-83 
intensive. Cannulation (or administration of intramuscular Synacthen) and venous 84 
sampling may be distressing and painful, especially for children. These barriers may 85 
lead to delayed or missed diagnoses, with a risk of death through an adrenal crisis.5 86 
There is a need for a less invasive, less resource-intensive, therefore more cost-87 
effective, test for AI.  88 
The label for Synacthen recommends a 250 µg intravenous dose; however, in clinical 89 
practice, both a high- and low-dose test are used as 250 µg provides a 90 
supraphysiological dose of Synacthen.3 Meta-analyses demonstrate similar outcomes 91 
for both the high- and low-dose test.6,7 There is a threshold tetracosactide level that 92 
elicits a maximal cortisol response at 30 minutes and this is achieved with 1 µg 93 
intravenous Synacthen, with higher doses generating more prolonged stimulation.8-10 94 
Salivary cortisol is a validated and well established alternative to invasive 95 
glucocorticoid sampling.11 It has been investigated as an alternative to plasma cortisol 96 
following the administration of Synacthen in both healthy volunteers and patient 97 
populations.12-14 Salivary cortisone is emerging as the preferable salivary biomarker as 98 
it is more abundant in saliva than cortisol, more sensitive at low plasma cortisol levels, 99 
and better reflects plasma total and free cortisol than salivary cortisol.12-16  100 
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We have investigated alternative routes for Synacthen administration. The intranasal 101 
route has advantages: minimal training to administer drugs in a rapid and tolerable way; 102 
good absorption due to the richly vascular nasal mucosa; avoidance of first pass 103 
metabolism; and a rapid onset of action.17 The side effects of intranasal drugs are few 104 
and are generally attributable to the drug itself rather than the method of delivery. 105 
Previous studies have examined the potential of nasally administered ACTH analogues 106 
but as a replacement for depot ACTH, historically used as an alternative to 107 
corticosteroid treatment in inflammatory conditions. Despite a demonstrable adrenal 108 
response, the short duration of Synacthen activity limited their therapeutic 109 
advancement.18,19 We have developed an intranasal formulation of Synacthen and 110 
tested it in both adults and children, with the aim of generating a non-invasive test. 111 
 112 
Materials and Methods 113 
Studies design and participants  114 
We conducted five studies (S1-S5) at the Clinical Research Facilities of Sheffield 115 
Children’s NHS Foundation Trust and Sheffield Teaching Hospitals NHS Trust, UK 116 
between 2010 and 2017. Studies S1-3 and S5 were open-label, multi-arm, sequence-117 
randomised, crossover, pharmacodynamic (PD) studies. S4 was a repeatability study. 118 
Studies S1-S4 were conducted in healthy adult males and study S5 in healthy children. 119 
As a “first in man” study, ethical restrictions precluded administration of the novel drug 120 
product to women of childbearing age. The numbers assessed for eligibility, recruited, 121 
completing study visits and included in data analyses for each study are displayed in 122 
the CONSORT table (table 1). We recruited 12 different adults to each of the 123 
pharmacodynamic studies, with six volunteers from the dose-response study (S3) re-124 
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enrolled for the repeatability study (S4), and 24 children participating in the paediatric 125 
study (S5). We excluded volunteers if they smoked, had been diagnosed with an 126 
endocrinopathy, intra-cranial or adrenal pathology, asthma, allergic rhinitis, anaemia, 127 
peptic ulcer disease, gastrointestinal bleed or dyspepsia, experienced a severe allergic 128 
reaction or any hypersensitivity to synacthen, were on any regular or prescribed 129 
medication, received any formulation of corticosteroid in the previous three months or 130 
had ever had a course of oral corticosteroids lasting more than one month. The first 131 
study was approved by Leeds (West) Research Ethics Committee, UK and all 132 
subsequent studies by London-Hampstead Research Ethics Committee, UK. Written 133 
informed consent was given by all participants or their parents/carers. The studies were 134 
registered with EudraCT (2009-013355-29 and 2012-003241-15).  135 
 136 
Nasal tetracosactide formulations  137 
Our initial study (S1) used 25 µg and 100 µg of the licenced intravenous Synacthen 138 
formulation (250 µg/ml, Alliance Pharmaceuticals Wiltshire, UK) which we 139 
administered intranasally. Doses were based on the results of a murine study but were  140 
poorly absorbed.20 For subsequent studies the tetracosactide was specifically 141 
manufactured (Archimedes Pharma, Nottingham, UK) presenting us with the 142 
opportunity to formulate with concentrations of tetracosactide (Bachem AG, 143 
Bubendorf, Switzerland) in volumes suitable for nasal administration (0·1-0·2 ml per 144 
nostril) and with chitosan (FMC BioPolymer AS, Sandvika, Norway), a drug enhancer 145 
to optimise nasal absorption. Chitosan, a polysaccharide comprising copolymers of 146 
glucosamine and N-acetyl-glucosamine, is derived by partial deacetylation of chitin 147 
from crustacea. It is a cationic biopolymer, acting as a bioadhesive film-forming agent 148 
to increase drug residence time in the nose, slow mucociliary clearance, and may 149 
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facilitate paracellular transport of large polar molecules. It is not systemically absorbed 150 
and has an excellent safety profile, with a multitude of applications including 151 
clarification agent, fungicide, nutritional supplement, and cosmetics constituent.17  152 
The nasal formulations we chose for the optimisation study (S2) examined the effects 153 
of chitosan addition, dose escalation and the additive effect of both. The nasal 154 
formulations were: Nasacthin001 containing 100 µg tetracosactide with chitosan (0·2 155 
ml of 0·5 mg/ml), Nasacthin002 containing 500 µg tetracosactide (0·2 ml of 2·5 156 
mg/ml), and Nasacthin003 containing 500 µg tetracosactide with chitosan (0·2 ml of 157 
2·5 mg/ml). Nasacthin003 was subsequently given in double dose (0·4 ml of 2·5 158 
mg/ml) to yield 1000 µg tetracosactide with chitosan.  159 
 160 
Procedures 161 
All studies were carried out employing a similar methodology. Participants were given 162 
1 mg (0·5 mg for under 8-year olds) dexamethasone the night before and the morning 163 
of each visit to establish a uniform glucocorticoid baseline and to allow for plasma 164 
tetracosactide quantification. We verified adherence by low or undetectable plasma 165 
cortisol (<50 nmol/L) on a baseline sample. Additionally in study 1 (S1) we tested -1 166 
minute (baseline) samples for plasma ACTH on an immunochemiluminmetric assay 167 
(Immulite 2000, Siemans Healthineers, Munich, Germany), verifying adherence as an 168 
ACTH level of <5 IU/L.  169 
All visits commenced before 09.30. Volunteers rested for 30 minutes following 170 
intravenous cannulation and remained supine throughout. Participants attended for 171 
nasal tetracosactide visits or the intravenous comparator visit (high-dose Synacthen 172 
(250 µg, 12 adults; 145 µg /m2, 12 children) or low-dose (1 µg, 23 adults, 12 children)) 173 
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in a randomised order, with no fewer than seven days between visits. Our dilution 174 
method for low-dose Synacthen has been described previously.14 We administered 175 
nasal preparations via a readily available, CE marked Mucosal Atomisation Device 176 
(Teleflex, Wayne, PA, USA), 0·1 ml to each nostril (0·2 ml for 1000 µg dose). Paired 177 
blood, taken from the indwelling cannula, and saliva samples, a minimum of 1 ml 178 
collected by passive drool into a Salicap tube (IBL, Hamburg, Germany), were taken 179 
at the following times (administration of tetracosactide at 0 minutes): -15, -1, 2, 5, 10, 180 
15, 20, 30, 40, 50, 60, 75, 90, and 120 minutes. We requested participants rinse their 181 
mouths thoroughly with water ten minutes before the first salivary sample and not to 182 
eat or drink anything, other than water, until after the final sample collection. 183 
Participants initiated the salivary drool at the same time the syringe was connected to 184 
the cannula to withdraw the discard, prior to blood sampling.  185 
The six participants we re-recruited from the dose response study (S3) to participate in 186 
the repeatability study (S4) underwent two further SST using 500 µg Nasacthin003 with 187 
sampling times at -1, 5, 10, 30, 40, 60 and 90 minutes. In the paediatric study (S5) we 188 
recruited 24 children, all of whom received the 500 µg Nasacthin003 formulation for 189 
their intranasal visit, but were randomised to receive either high-dose (145 µg/m2) or 190 
low-dose (1 µg) Synacthen as their intravenous comparator. After completion of their 191 
visits, participants were invited to complete a post-study questionnaire to gauge their 192 
personal experience of the intravenous and nasal tests.  193 
We froze and stored samples, batch analysing at the end of each of the five studies. 194 
There were no changes to the assay platforms between studies. We analysed plasma 195 
cortisol samples using the Abbott Architect i1000 chemiluminescent microparticle 196 
immunoassay (Abbott Diagnostics Ltd, Berkshire, UK). Our salivary cortisol and 197 
cortisone analyses were performed by a modified liquid chromatography-tandem mass 198 
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spectrometry (LC-MS/MS) assay using a Waters Xevo TQ-MS mass spectrometer and 199 
a Waters Acquity LC system with an electrospray source operated in positive-ionization 200 
mode. We have reported assay characteristics previously.14 In study S5 we measured 201 
plasma tetracosactide levels by an ACTH(1-24) EIA Kit (Peninsula Laboratories 202 
International, Inc., San Carlos, CA, USA). Assay sensitivity, 72 pg/ml; intra-assay 203 
precision, 2·73% (at 165 pg/ml) and 1·76% (at 400 pg/ml); and inter-assay precision 204 
9·32% (at 160 pg/ml) and 6·50% (at 412 pg/ml). The EIA ACTH(1-24) data sheet 205 
reports 100% cross-reaction with ACTH(1-39) in the assay. 206 
 207 
Randomisation  208 
We randomised formulation to participant visits in studies S2, S3 and S5 using an 209 
online randomisation programme. The randomisation used a block permutation method 210 
which created a balanced randomisation. The randomisation plan was produced for 20 211 
participants to allow for further volunteers to be randomised should any of the original 212 
recruits drop out.  213 
 214 
Outcomes 215 
Our primary outcome was to develop a non-invasive alternative to the intravenous SST. 216 
Our secondary outcomes were: comparison of plasma cortisol at different time points 217 
between the nasal and intravenous formulations; comparison of the response both 218 
within and between participants to assess repeatability; comparison of the response 219 
between children and adults; and (in the paediatric study only) comparison of the 220 
pharmacokinetic parameters (time to maximum plasma concentration (Tmax), 221 
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maximum plasma concentration (Cmax), area under the concentration time curve 222 
(AUC) and bioavailability) achieved.  223 
 224 
Statistical analysis 225 
We selected the sample size for each study in accordance with EMA bioavailability 226 
study guidance.21 Only participants who were adequately dexamethasone-suppressed 227 
and completed at least one nasal and the intravenous comparator visit were included in 228 
the final analyses (table 1). Our safety analysis includes all participants who received 229 
nasal formulations. We examined the plasma cortisol response to each formulation over 230 
time for each participant. In order to mirror the most popular sampling times following 231 
intravenous Synacthen we truncated cortisol response over time graphs at 60 minutes.3,4 232 
We used descriptive statistics, mean and standard deviation (SD) to describe the plasma 233 
cortisol, salivary cortisol and salivary cortisone response to each formulation of 234 
tetracosactide. Where participants had both formulations we used paired t-tests and 235 
where the formulations had been given to different participant groups we used 236 
independent samples t-tests to compare the difference of the peak plasma cortisol, 30-237 
minute and 60-minute cortisol between the intravenous comparator and the nasal 238 
formulation. A p value of less than 0·05 indicated a statistically significant difference. 239 
We used coefficient of variation (CV) to quantify the variability between formulations, 240 
between-participants and within-participants and standard deviations to further 241 
examine between-participant variability. Additionally, we assessed the within-242 
participant repeatability using data from study S4 to calculate a 30- and 60-minute 243 
repeatability coefficient. The repeatability coefficient is calculated from the within 244 
participant standard deviation (sw) as 1.96√2 sw  and describes the range within which 245 
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two observations on the same individual would be expected to fall 95% of the time. We 246 
used SAS v9·3 for statistical analyses. 247 
 248 
Pharmacokinetic (PK) analysis of Tetracosactide data in paediatric study (S5):  249 
We calculated the PK parameters: Tmax, Cmax, AUC from time zero until the last 250 
quantifiable time point (AUC0-t) and AUC from time zero until infinity (AUC0-) for 251 
each individual using non compartmental analysis in Phoenix WinNonLin 6·4. For 252 
determination of AUC values we used the linear up and log down trapezoidal method. 253 
For AUC0-∞ the terminal slope (Lambda Z) of the concentration-time profile was 254 
determined using the ‘Best fit’ method in WinNonLin. We obtained descriptive 255 
statistics for the PK parameters for the intravenous and nasal tetracosactide 256 
formulations. The absolute bioavailability of the Nasacthin003 was calculated based on 257 
AUC0-∞ compared to the intravenous Synacthen 250 µg dose. 258 
 259 
Results  260 
Participants: We enrolled the first participant to study S1 on July 7, 2010 and the last 261 
to study S5 on August 17, 2017. The numbers screened for eligibility, participating in 262 
each study and included in the final analyses are displayed in table 1. The adult studies 263 
(S1-S4) recruited 36 healthy males, aged 19-46 years (median 22, IQR 21·5-23·0), with 264 
BMIs of 19·1-29·4 kg/m2 (median 23·2, IQR 21·7-24·4). There was no indication that 265 
BMI influenced the efficacy of the nasal formulations. In the paediatric study (S5) we 266 
recruited 36 children but 12 did not complete their initial visit due to unsuccessful 267 
cannulation or difficulties obtaining samples and did not continue in the study. Thus, 268 
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24 healthy children (12F) participated, aged 5-14 years (median 10·5, IQR 9·0-12·5), 269 
with BMIs between the 4th-93rd centiles (median 51·5, IQR 31·5-74·0).  270 
 271 
Formulation development and optimisation (table 1 and 2): These were based on 272 
the pharmacodynamic cortisol response to Synacthen. Our initial study (S1) used a 273 
commercially available intravenous formulation of Synacthen administered 274 
intranasally at 25 and 100 µg and the peak cortisol response was significantly lower 275 
when compared to the 1 µg intravenous comparator (mean difference and 95% 276 
confidence interval: -320 nmol/L (-370, -271) and -222 nmol/L (-297, -146), p<0·0001 277 
and p=0·0001 respectively). We then tested three novel intranasal formulations (study 278 
S2) to examine the effect of dose escalation and the addition of the mucoadhesive 279 
chitosan: Nasacthin001 (100 µg tetracosactide with chitosan), Nasacthin002 (500 µg 280 
tetracosactide) and Nasacthin003 (500 µg tetracosactide with chitosan). The peak 281 
cortisol responses showed an increase with the addition of chitosan with mean 282 
difference (95% confidence interval): 177 nmol/L (54, 299) p=0·007 for 100 µg 283 
formulation and 222 nmol/L (73, 370) p=0·01 for 500 µg formulation. The increase in 284 
dose from 100 to 500 µg also significantly increased the cortisol response: 242 nmol/L 285 
(112, 372) p=0·0011 for formulations without chitosan and 339 nmol/L (137, 541) 286 
p=0·0063 for formulations with chitosan. We therefore selected to progress with 287 
formulation Nasacthin003 (500 µg tetracosactide and chitosan) for studies S3, S4 and 288 
S5 as it gave the maximal cortisol response. 289 
 290 
Nasacthin003 compared to intravenous Synacthen (table 3, figure 1): We compared 291 
250 µg intravenous Synacthen with Nasacthin003 at 500 µg and 1000 µg in study S3. 292 
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As can be seen in figure 1a the mean plasma cortisol concentrations of all three 293 
formulations are similar up to 60 minutes. There was no significant difference in the 294 
60-minute plasma cortisol between either the 500 µg or 1000 µg Nasacthin003 nasal 295 
formulation compared with 250 µg intravenous Synacthen, with mean difference (95% 296 
confidence interval): -28 nmol/L (-70, 14) p=0·17 and -16 nmol/L (-48, 16) p=0·30, 297 
respectively. For salivary cortisol and cortisone the shape of the curve was similar 298 
following administration with both 250 µg intravenous Synacthen and Nasacthin003 299 
(figure 1b, 1c). However, the salivary cortisol and cortisone levels at 60 minutes were 300 
lower following intranasal administration. The mean difference (95% confidence 301 
interval) for salivary cortisol and cortisone at 1000 µg was -1·5 nmol/L (-3·8, 0·7) 302 
p=0·16 and -5·2 nmol/L (-7·5, -2·8) p=0.0005 respectively and at 500 µg was -4·5 303 
nmol/L (-8·3, -0·6) p=0·028 and -8·4 nmol/L (-15·2, -1·6) p=0·02, respectively. 304 
 305 
Reproducibility: The between-participant variability of cortisol response at 60 306 
minutes, represented by the standard deviation, calculated using all participants who 307 
received 500 µg Nasacthin003 (n=46, excluding repeated observations), was 95 nmol/L 308 
for plasma cortisol, 7 nmol/L for salivary cortisol and 14 nmol/L for salivary cortisone. 309 
The CVs were 18%, 32%, and 24% respectively and were significantly different (all 310 
pairwise comparisons p<0.0001). For participants receiving 250 µg intravenous 311 
Synacthen (n=23) the standard deviation was 60 nmol/L for plasma cortisol, 7 nmol/L 312 
for salivary cortisol and 12 nmol/L for salivary cortisone. The CVs were 11%, 30%, 313 
21% respectively and were significantly different (all pairwise comparisons p<0.0001). 314 
The within-subject variability (CV) for the cortisol response at 60 minutes in six 315 
participants who received 500 µg Nasacthin003 on three separate occasions (studies S3 316 
and S4) ranged from 1·0% to 11·2% for plasma cortisol, 1·1% to 31·4% for salivary 317 
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cortisol and 3·1% to 23·4% for salivary cortisone (figure 2). Additionally we assessed 318 
the within-participant variability of plasma cortisol by calculation of a repeatability 319 
coefficient, which was 70·6 nmol/L at 30 minutes, such that two observations on the 320 
same individual would be expected to fall within -70·6 and +70·6 nmol/L plasma 321 
cortisol for 95% of the time. At 60 minutes the repeatability coefficient was 104·6 322 
nmol/L. The repeatability coefficients calculated for the 60-minute concentration of 323 
salivary cortisol and cortisone were 10·3 and 21·1 nmol/L respectively. 324 
 325 
Nasacthin003 in children (S5) (figure 3): All 24 participating children received 500 326 
µg Nasacthin003. Half received 1 µg (low-dose) intravenous Synacthen as their 327 
comparator and the other half 145 µg/m2 (high-dose) intravenous Synacthen and the 328 
results were compared to those in adults from studies S2 and S3 (table 3). We found no 329 
significant difference in the peak, 30- and 60-minute plasma cortisol between adults 330 
and children for 500 µg Nasacthin003 or either of the two intravenous Synacthen doses. 331 
There was no significant difference in the 60-minute plasma cortisol between the 500 332 
µg Nasacthin003 formulation compared with 250 µg intravenous Synacthen with mean 333 
difference (95% confidence interval): -15·9 nmol/L (-46·1, 14·4) p=0·26. Similarly we 334 
found no difference at 60 minutes when measuring the glucocorticoid response in 335 
saliva: mean difference (95% confidence interval): -3·8 nmol/L (-7·7, 0·2) p=0·06 for 336 
salivary cortisol and -5.8 nmol/L (-14·7, 3·1) p = 0·17 for salivary cortisone. 337 
 338 
Absolute bioavailability of Nasacthin003 (S5) (table 4, figure 4): A summary of the 339 
pharmacokinetic results from the paediatric cohort are shown in table 4. Our calculated 340 
absolute bioavailability of 500 µg Nascthin003 against intravenous 145 µg/m2 341 
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Synacthen was 0·143 (14·3%). The mean AUC0-inf for Nasacthin003 was over three-342 
fold higher than the 1 µg intravenous Synacthen test (figure 4) but approximately a 343 
third that of the 145 µg/m2 intravenous dose. Similarly, the mean Cmax for 344 
Nasacthin003 was higher than for 1 µg intravenous Synacthen (433 versus 245 pg/mL) 345 
but lower than the 145 µg/m2 intravenous Synacthen test (433 versus 6702 pg/mL). 346 
 347 
Safety: We found nasal tetracosactide formulations to be well tolerated by adults and 348 
children. We administered a total of 70 doses of Nasacthin003 to 46 subjects (22 adults, 349 
24 children) with no serious adverse events (SAEs). Whilst 32% of participants did not 350 
report adverse events, the 68% who did experienced events that were anticipated 351 
following nasal drug administration; specifically watery eyes, coughing, sneezing, and 352 
a vinegary taste (acetic acid is a constituent of the drug product). These were all mild, 353 
with full and rapid resolution, and considered to be treatment-related. In addition, 12 354 
doses of Nasacthin001, 12 doses of Nasacthin002, and 11 doses of 25 µg and 100 µg 355 
Synacthen were all administered intranasally with no SAEs reported. On post-study 356 
questionnaires the majority of participants (77%) reported nasal administration to be 357 
“easy” or “very easy”, receiving the nasal drug as “no problem” or “slightly unpleasant” 358 
(86%) and “much the same”, “better”, or “much better” compared to the intravenous 359 
administration (71%).  360 
 361 
Discussion  362 
Over our four open-label multi-arm, sequence-randomised, crossover, 363 
pharmacodynamic studies we found 500 µg Nasacthin003 to demonstrate an equivalent 364 
plasma cortisol response to the intravenous SST at 60 minutes. Our repeatability study 365 
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demonstrated between and within-individual reproducibility of the test and the 366 
glucocorticoid response in children was indistinguishable from that of adults.  367 
Our early studies tested six different doses from four formulations of tetracosactide. 368 
The response threshold required for maximal adrenal stimulation was not reached with 369 
intranasal doses derived from the commercially available intravenous formulation at 25 370 
and 100 µg. The current 250 µg SST is widely recognised to deliver a 371 
supraphysiological adrenal stimulus. Studies attempting to quantify the ACTH level 372 
required to maximally stimulate the adrenal gland are decades old and hampered by 373 
assay issues but quote between 60-80 pg/ml, approximately half the endogenous peak 374 
values seen in healthy subjects in the early morning.9,22 This is considerably lower than 375 
the levels generated following intravenous administration with 250 µg Synacthen 376 
(1580-66,000 pg/ml) but closer to those measured following administration of 1 µg 377 
(3·5-1920 pg/ml), leading some to advocate the 1 µg test as more physiological.9,22 378 
Groups comparing the low-dose and high-dose SST have demonstrated an equivalent 379 
cortisol response at 30 minutes, indicating that 1 µg is adequate to achieve maximal 380 
adrenal stimulation, but responses diverge thereafter, thought to be due to continued 381 
adrenocortical stimulation with higher doses.8-10,14 In our studies, the addition of the 382 
nasal drug enhancer, chitosan, and dose escalation both significantly improved 383 
absorption of tetracosactide and the resultant glucocorticoid response, yielding plasma 384 
tetracosactide levels sufficient to maximally stimulate the adrenal cortex. Additionally 385 
our PK analysis demonstrated tetracosactide levels in excess of those seen after 386 
stimulation with 1 µg of intravenous Synacthen. The 500 µg Nasacthin003 dose was 387 
chosen for further study as it demonstrated that it exceeded the threshold for maximal 388 
adrenal stimulation, with no difference in plasma cortisol levels at 60 minutes when 389 
compared to the 250 µg intravenous test.  390 
18 
The SDs and CVs for the cortisol response at 60 minutes for 500 µg Nasacthin003 were 391 
higher than for 250 µg intravenous Synacthen. To our knowledge between-participant 392 
repeatability has not previously been reported for the 250 µg intravenous SST. We 393 
demonstrated CVs at 60 minutes post-stimulation, both within and between-394 
participants, for the intranasal preparation which were better than that previously 395 
published for low-dose intravenous Synacthen. Within-participant CVs ranged from 396 
3·0-16·4% in one study and 46·7-57·2% in another, with between-participant 28·0-397 
48·6%.23,24 398 
Analogues of ACTH, including ACTH(1-24) (Synacthen/Cosyntropin) have been 399 
administered nasally in historical studies for treatment, but the investigation for 400 
diagnostic purposes is novel.18,19 Synacthen is inactivated in the gastrointestinal tract 401 
by proteolytic enzymes and therefore needs parenteral administration. It is a large polar 402 
molecule with a molecular mass of 2932 g/mol. These are not ideal properties for a 403 
nasal drug, which tend to be small and lipophilic. Drugs with a molecular weight below 404 
1000 g/mol generally do not require adjuvants for effective absorption but larger 405 
peptide molecules benefit from the increased drug residence times, by slowing 406 
mucociliary clearance, and modifying transmembrane transportation.17 The nasal route 407 
for proteins of a similar size has been previously investigated. For example, 408 
desmopressin (1069 g/mol) has a bioavailability of approximately 10% of the 409 
intravenous route and salmon calcitonin (3455 g/mol) has a relative bioavailability of 410 
between 3·9% and 7·9% when delivered with the enhancer sodium tauro-24,25-411 
dihydrofusidate.25 Improved Synacthen absorption with the addition of nasal drug 412 
enhancers (sodium glycocholate and bacitracin) has been demonstrated in a murine 413 
study but the combination of tetracosactide and chitosan to promote nasal absorption is 414 
novel.20  415 
19 
The method of diagnosis of AI by the SST has been much debated. Points of discussion 416 
include: what dose of Synacthen to administer, which cortisol assay platform to analyse 417 
on and what sampling times and diagnostic criteria to employ. Our recently published 418 
international survey on SSTs reported widespread variation including cortisol sampling 419 
timings and interpretative thresholds.3 Our non-invasive test affords the opportunity for 420 
research in large cohorts where controversies exist over diagnosis and management, in 421 
particular monitoring and testing of patients on glucocorticoids at risk of AI. Termed 422 
tertiary AI this is now thought to be the commonest cause of AI in the Western world.2 423 
Nearly 1% of the UK adult population are on oral glucocorticoids at any one time and 424 
4·5% of UK children are prescribed inhaled glucocorticoids, 10% above the 425 
recommended dose.26,27 Biochemical evidence of AI has been reported in up to 40% of 426 
children taking inhaled glucocorticoids.28-30 The potential global clinical utility of a test 427 
that can be administered in the outpatient setting or the community offers the potential 428 
for cost savings by negating the need for day case admission to hospital.  429 
The relationship between plasma cortisol and salivary cortisol and cortisone has been 430 
widely published.13-15 Salivary glucocorticoid estimation is growing in popularity, as 431 
salivary glucocorticoids reflect plasma cortisol and sampling is more pleasant for 432 
patients. Late night salivary cortisol testing is a first line investigation in Cushing 433 
Syndrome.11 Cortisone is the more abundant glucocorticoid in saliva as plasma free 434 
cortisol and salivary cortisol are rapidly converted to inactive cortisone by 11ß-435 
hydroxysteroid dehydrogenase type 2, making it better suited for the diagnosis of 436 
AI.13,15,16 Sixty minutes is the optimal timing of salivary glucocorticoid sampling 437 
following stimulation with intravenous Synacthen.14 The salivary cortisol and cortisone 438 
responses in children were similar between Nasacthin003 and intravenous Synacthen 439 
but slightly lower in adults. This may represent a dose effect in adults although, as 440 
20 
discussed above, the evidence suggests Nasacthin003 exceeds the threshold for 441 
maximal stimulation. It will be important, when introducing the non-invasive intranasal 442 
test into clinical practice, to perform clinical trials to define normal ranges for salivary 443 
cortisol and cortisone and document the sensitivity and specificity to diagnose adrenal 444 
insufficiency. 445 
There are a number of limitations of our studies. All our studies were conducted in 446 
healthy adult and child volunteers who were dexamethasone suppressed. However, this 447 
conferred considerable advantage; uniformity between subjects and a clean baseline 448 
from which to assess response to tetracosactide formulations, and perform PK 449 
modelling. We acknowledge the lack of a patient cohort, although our intention was to 450 
demonstrate equivalence with a diagnostic agent that has been in widespread use for 451 
more than 30 years, not redefine the SST. We employed different assay platforms for 452 
plasma cortisol (immunoassay) and the salivary glucocorticoids (LCMS). This was 453 
pragmatic and reflected analytical techniques employed in clinical practice. We used 454 
an in-house assay for plasma cortisol analysis and sent salivary samples to a laboratory 455 
with significant expertise in salivary steroid analysis, as this was not available at the 456 
time in our institution. In order to be able to combine the results the same assays were 457 
used for all samples across the five studies.  458 
In conclusion, we have developed a non-invasive alternative to the SST, with the 459 
administration of intranasal 500 µg Nasacthin003 and measurement of either salivary 460 
cortisone or cortisol at baseline and 60 minutes. Nasacthin003 was well tolerated and 461 
in 70 doses administered to 46 participants only minor, short-lived, and anticipated 462 
adverse events were experienced. The new test could positively impact on the growing 463 
demand for adrenal function testing. It could be conducted globally in community and 464 
21 
outpatient settings, with potential cost savings, and reduced healthcare burden to 465 
patients.  466 
467 
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Table 1. CONSORT TABLE: Overview of the five studies. 
 
Table 2: Maximum glucocorticoid responses to different doses and formulations of 
tetracosactide administered in studies 1 (S1) and 2 (S2). Data displayed as mean and 
standard deviation (SD). 
 
Table 3: Summary of adult and paediatric glucocorticoid response following tetracosactide 
challenge by single dose administration of 250 µg or 1 µg intravenous Synacthen or 500 µg 
Nasacthin003. 
 
Table 4: Summary of paediatric pharmacokinetic parameters for plasma tetracosactide 
following administration of intravenous Synacthen and Nasacthin003 in Study S5. AUC0-inf, 
area under the concentration-time curve extrapolated to infinity; AUC0-Last, area under the 
concentration-time curve to last measurable concentration; Cmax maximum plasma concentration; 
CI, confidence interval; F, bioavailability; GM, geometric mean; Tmax, time of maximum 
concentration.  
 
Figure 1. Mean plasma cortisol (1a), salivary cortisol (1b) and salivary cortisone (1c) 
concentration over time following single dose administration of 250 µg intravenous 
Synacthen (red line), 500 µg Nasacthin003 (blue line) and 1000 µg Nasacthin003 (green line) 
in dexamethasone-suppressed healthy adult male participants. SD shown as error bars.  
 
Figure 2. Individual plasma cortisol concentration over time graphs following three separate 
single dose administrations of 500 µg Nasacthin003 in dexamethasone-suppressed healthy 
adult male participants.  
 
Figure 3. Mean plasma cortisol (3a), salivary cortisol (3b) and salivary cortisone (3c) 
concentration over time following single dose administration of 250 µg intravenous 
Synacthen (red line) and 500 µg Nasacthin003 (blue line) in dexamethasone-suppressed 
healthy children. SD shown as error bars. 
 
Figure 4: Mean plasma tetracosactide concentration over time following single dose 
administration of 1 µg intravenous Synacthen (purple line) and 500 µg Nasacthin003 (blue 



































target = 12 Synacthen: 
single nasal dose, 25 µg and 100 µg 
single iv dose, 1 µg 
 
N = 114 
N = 12 
 
N = 10 
N = 12 
Screened for 
eligibility = 132 












target = 12 
Nasacthin001, single nasal dose, 100 µg 
Nasacthin002, single nasal dose, 500 µg 
Nasacthin003, single nasal dose, 500 µg 
Synacthen, single iv dose, 1 µg 
N = 12 
N = 12 
N = 105 
N = 115 
N = 10 
N = 12 
N = 8 
N = 10 
Screened for 
eligibility = 12 










target = 12 Nasacthin003, single nasal dose, 500 µg 
Nasacthin003, single nasal dose, 1 mg 
Synacthen, single iv dose, 250 µg 
N = 12 
N = 12 
N = 12 
N = 11 
N = 12 
N = 12 
Screened for 
eligibility = 12 










target = 6 
Participants received two further doses of: 
Nasacthin003, single nasal dose, 500 µg 
 
N = 6 
 
N = 6 











target = 24 
(12F) 
Nasacthin003, single nasal dose, 500 µg 
Synacthen, single iv dose, 1 µg 
Synacthen, single iv dose, 250 µg 
N = 24  
N = 12 
N = 12 
N = 23 
N = 9 
N = 11 
Screened for 
eligibility = 36 
 
1. Order of visits was randomised for studies S2, S3 and S5; visits separated by a minimum of one week. 
2. Participant screened but excluded due to mild asthma 
3. Nasacthin001, 100 µg tetracosactide and chitosan; Nasacthin002, 500 µg tetracosactide; Nasacthin003, 500 µg 
tetracosactide and chitosan. 
4. Participant failed to attend subsequent visits 
5. Participants removed from study due to mild gastrointestinal side-effects to dexamethasone 
6. Number of participants completing the study and included in final data analyses. Dexamethasone suppression 
confirmed by baseline undetectable/low cortisol (<50 nmol/L), and subjects excluded from analysis if not 




Table 2: Maximum glucocorticoid responses to different doses and formulations of 
tetracosactide administered in studies 1 (S1) and 2 (S2). Data displayed as mean and 
standard deviation (SD). 
 
 








Study Dose      
S1 Intranasal Synacthen 
100 µg 
 N 9 10 10 
Mean 159.6 1.1 8.1 
SD 95.0 0.6 6.5 
Intranasal Synacthen 
25 µg  
 N 10 10 10 
Mean 63.9 1.0 3.5 
SD 57.7 0.5 2.8 
Intravenous Synacthen  
1 µg  
 N 11 11 11 
Mean 388.2 7.2 29.1 
SD 48.6 4.0 7.7 
S2 Nasacthin001  
100 µg  
 N 11 11 11 
Mean 336.1 8.6 34.7 
SD 160.8 7.2 22.8 
Nasacthin002  
500 µg 
 N 12 12 12 
Mean 401.6 16.2 55.2 
SD 183.7 14.3 38.0 
Nasacthin003  
500 µg 
 N 8 8 8 
Mean 648.7 28.7 82.1 
SD 141.0 12.9 23.9 
Intravenous Synacthen  
1 µg 
 
 N 10 10 10 
Mean 391.4 10.2 39.5 




Table 3: Summary of adult and paediatric glucocorticoid response following tetracosactide challenge by single dose administration of 250 µg or 




Parameter (all nmol/L) 
Nasacthin003, 500 µg intranasal 
 
Synacthen, 250 µg intravenous 
 
















































































































































           

























































































































           
















































































Number of subjects 
 
Adult: N=19 (31 doses) Children: N=23 
 
 
Adult: N=12 Children: N=11 
 
 





Table 4: Summary of paediatric pharmacokinetic parameters for plasma tetracosactide 
following administration of intravenous Synacthen and Nasacthin003 in Study S5. 
AUC0-inf, area under the concentration-time curve extrapolated to infinity; AUC0-Last, area 
under the concentration-time curve to last measurable concentration; Cmax maximum plasma 




GM (95% CI); 
Median (range) for Tmax 
Nasacthin003  Synacthen  



























(0·082–0·249) - - 
Tmax (mins)  
Median (range) 
10 
(5–20) - - 
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Figure 1. Mean plasma cortisol (1a), salivary cortisol (1b) and salivary cortisone (1c) 
concentration over time following single dose administration of 250 µg intravenous Synacthen 
(red line), 500 µg Nasacthin003 (blue line) and 1000 µg Nasacthin003 (green line) in 











Figure 2. Individual plasma cortisol concentration over time graphs following three 
separate single dose administrations of 500 µg Nasacthin003 in dexamethasone-suppressed 
















Figure 3. Mean plasma cortisol (3a), salivary cortisol (3b) and salivary cortisone (3c) 
concentration over time following single dose administration of 250 µg intravenous 
Synacthen (red line) and 500 µg Nasacthin003 (blue line) in dexamethasone-suppressed 





















Figure 4: Mean plasma tetracosactide concentration over time following single dose 
administration of 1 µg intravenous Synacthen (purple line) and 500 µg Nasacthin003 (blue 
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